Related Experiment Video
Updated: Sep 12, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
The role of SMARCA4 in lung cancer
Guimei Wang1, Guoqi Zhou2, Weidong Han3
1Department of Pulmonary and Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Abstract:
Lung cancer remains one of the leading causes of mortality among cancer patients. Chromatin remodeling is a crucial epigenetic process in cancer, primarily regulated by alterations in genes encoding subunits of the switch/sucrose non-fermentable (SWI/SNF) complex. SMARCA4 and SMARCA2 are two mutually exclusive catalytic subunits within the SWI/SNF complex responsible for utilizing ATP hydrolysis to provide energy for chromatin remodeling. In lung cancer, SMARCA4 is one of the most common mutated subunits of the SWI/SNF complex. Patients with SMARCA4-deficient lung cancer typically experience poorer clinical outcomes. At present, there is no established targeted therapy designed specifically for this type of cancer. Here, we mainly discuss the mechanisms of SMARCA4 in lung cancer development and progression, its co-mutations and mutually exclusive mutations, cellular origin, clinical pathological characteristics, diagnosis and treatment of SMARCA4-deficient lung cancer. We also investigate the concept of synthetic lethality between SMARCA4 and SMARCA2, along with susceptibility to SMARCA4-deficient lung cancer and potential applications of immunotherapy.
Insights
Lung cancer often involves mutations in the SMARCA4 gene, a key part of the SWI/SNF complex. This deficiency leads to poor outcomes, highlighting the need for targeted therapies for SMARCA4-deficient lung cancer.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Lung cancer is a leading cause of cancer mortality.
- Chromatin remodeling, regulated by the SWI/SNF complex, is vital in cancer.
- SMARCA4 is frequently mutated in lung cancer, correlating with poor prognosis.
Purpose of the Study:
- To discuss mechanisms of SMARCA4 in lung cancer development and progression.
- To explore co-mutations, cellular origin, and clinical characteristics of SMARCA4-deficient lung cancer.
- To investigate synthetic lethality and immunotherapy applications for this subtype.
Main Methods:
- Review of existing literature on SMARCA4 in lung cancer.
- Analysis of mutation patterns, including co-mutations and mutually exclusive mutations.
- Exploration of synthetic lethality principles and immunotherapy potential.
Main Results:
- SMARCA4 deficiency is linked to poorer outcomes in lung cancer patients.
- SMARCA4 and SMARCA2 exhibit mutually exclusive roles within the SWI/SNF complex.
- Understanding these mechanisms may reveal therapeutic vulnerabilities.
Conclusions:
- SMARCA4-deficient lung cancer lacks targeted therapies, necessitating further research.
- Synthetic lethality strategies targeting SMARCA4 deficiency show promise.
- Immunotherapy may offer new treatment avenues for SMARCA4-mutated lung cancers.
Related Concept Videos
02:23Abnormal Proliferation
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...